Spots Global Cancer Trial Database for Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma
Official Title: An Open-Label Surgical Window of Opportunity Study Evaluating Pharmacodynamic Response of Orally Administered BAY 2402234 in Subjects With Recurrent Glioma, IDH Mutant, Grade 3 or 4
Study ID: NCT05061251
Interventions
Study Description
Brief Summary: This study aims to look at how BAY 2402234 responds in body in patients with recurrent glioma.
Detailed Description: To characterize the biological activity of BAY 2402234 in recurrent glioma, IDH-mutant, Grade 3/4 using liquid chromatography-mass spectrometry (LC-MS). The tissue orotate:carbamoyl aspartate ratio will serve as the primary pharmacodynamic biomarker and will be characterized via LC-MS.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Kalil g Abdullah, MD, MSc
Affiliation: UT Southwestern/ Simmons CC
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
